Overview of computational methods employed in early-stage drug discovery

被引:7
|
作者
Skjevik, Age Aleksander [1 ]
Teigen, Knut [1 ]
Martinez, Aurora [1 ]
机构
[1] Univ Bergen, Dept Biomed, N-5009 Bergen, Norway
关键词
INTERACTION ENERGY METHOD; MOLECULAR-MECHANICS; STRUCTURAL GENOMICS; PERTURBATION METHOD; COMBINING DOCKING; SCORING FUNCTIONS; LIGAND DOCKING; BINDING; DESIGN; STATE;
D O I
10.4155/FMC.09.7
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The understanding of biomolecular interactions ultimately depends on knowledge about the structural and dynamic details of the interacting system. Rational structure-based drug design implements computational methodology in this rationale. Discussion: Together with increasing throughput of structural biology, molecular modeling has progressively contributed to rational drug design and elucidation of nontoxic and patient-tailored interventions, helping to make drug development more cost-efficient. But in this challenging time for the pharmaceutical industry, the successful discovery of novel therapeutics should rely on integration of computational modeling with experimentation when it comes to ligand-binding energetics, system flexibility and genetic diversity/heterogeneity of the target. Moreover, it appears that many drugs even those for which specific receptors have been identified intercalate in biological membranes, which could also become the actual target. Conclusions: Understanding the drug-target and drug-unwanted-target interactions at the atomic level is fundamental in the initial phases of the drug development process. Molecular dynamics simulations and complementary computational methods are already contributing in this endeavor for the soluble pharmacological targets and show an increasing importance in the understanding of membrane-ligand interactions.
引用
收藏
页码:49 / 63
页数:15
相关论文
共 50 条
  • [21] Drug Treatment for Early-Stage COPD
    Ko, Fanny W. S.
    Wong, Gary W. K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (10): : 988 - 989
  • [22] Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy
    Yin, Guowei
    Lv, Guohua
    Zhang, Jerry
    Jiang, Hongmei
    Lai, Tianqi
    Yang, Yushan
    Ren, Yong
    Wang, Jing
    Yi, Chenju
    Chen, Hao
    Huang, Yun
    Xiao, Chaoni
    PHARMACOLOGY & THERAPEUTICS, 2022, 236
  • [23] Early-stage drug discovery reveals new targets for the treatment of Merkel cell carcinoma
    Garman, K.
    Gelb, T.
    Urban, D.
    Hall, M.
    Brownell, I.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S123 - S123
  • [24] A data science roadmap for open science organizations engaged in early-stage drug discovery
    Edfeldt, Kristina
    Edwards, Aled M.
    Engkvist, Ola
    Guenther, Judith
    Hartley, Matthew
    Hulcoop, David G.
    Leach, Andrew R.
    Marsden, Brian D.
    Menge, Amelie
    Misquitta, Leonie
    Mueller, Susanne
    Owen, Dafydd R.
    Schuett, Kristof T.
    Skelton, Nicholas
    Steffen, Andreas
    Tropsha, Alexander
    Vernet, Erik
    Wang, Yanli
    Wellnitz, James
    Willson, Timothy M.
    Clevert, Djork-Arne
    Haibe-Kains, Benjamin
    Schiavone, Lovisa Holmberg
    Schapira, Matthieu
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [25] Using Domain-Knowledge to Assist Lead Discovery in Early-Stage Drug Design
    Dash, Tirtharaj
    Srinivasan, Ashwin
    Vig, Lovekesh
    Roy, Arijit
    INDUCTIVE LOGIC PROGRAMMING (ILP 2021), 2022, 13191 : 78 - 94
  • [26] COORDINATING KNOWLEDGE CREATION IN MULTIDISCIPLINARY TEAMS: EVIDENCE FROM EARLY-STAGE DRUG DISCOVERY
    Ben-Menahem, Shiko M.
    von Krogh, Georg
    Erden, Zeynep
    Schneider, Andreas
    ACADEMY OF MANAGEMENT JOURNAL, 2016, 59 (04): : 1308 - 1338
  • [27] Computational Methods May Speedup Drug Discovery
    ZHANG Xiaomin
    Bulletin of the Chinese Academy of Sciences, 2020, 34 (03) : 189 - 189
  • [28] Opportunities and Challenges in Early-Stage TB Drug Discovery: Targeting DNA Replication as a Case Study
    Mizrahi, Valerie
    Chengalroyen, Melissa
    Lynch, Sasha
    Mason, Mandy
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2025, 152
  • [29] The BlueScreen-384 Assay as an Indicator of Genotoxic Hazard Potential in Early-Stage Drug Discovery
    Simpson, Kate
    Bevan, Nicola
    Hastwell, Paul
    Eidam, Patrick
    Shah, Poonam
    Gogo, Elke
    Rees, Steve
    Brown, Andrew
    JOURNAL OF BIOMOLECULAR SCREENING, 2013, 18 (04) : 441 - 452
  • [30] The Ukrainian Factor in Early-Stage Drug Discovery in the Context of Russian Invasion: The Case of Enamine Ltd
    Kondratov, Ivan S.
    Moroz, Yurii S.
    Grygorenko, Oleksandr O.
    Tolmachev, Andrey A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, : 992 - 996